Scroll for more

About

 

Steven Caffé, M.D.
Senior Vice President, Global PV, Regulatory Affairs & Quality

 

Dr. Caffé became our Senior Vice President for Regulatory Affairs in October 2014. He is accountable for Patient Safety, Regulatory Affairs and Corporate Quality globally.

Prior to joining Sucampo, Dr. Caffé was Chief Development and Regulatory Officer at AMAG Pharmaceuticals, a specialty pharmaceutical company.

 Prior, he served as Senior Vice President, Head of Global Regulatory Affairs and Patient Safety, at MedImmune LLC, the global biologics arm of AstraZeneca. He also served as Head of Global Regulatory Affairs and Pharmacovigilance, and co-chair of the Corporate Quality Council at Baxter International.

Dr. Caffé was Vice President and Head of Global Regulatory Development at Aventis/Sanofi, and held increasing leadership roles at Merck & Co. in Clinical and Regulatory Development from 1992 to 2005.

Dr. Caffé earned a doctorate medical degree from Université Pierre et Marie Curie (Paris 6), Faculté de Médecine Saint-Antoine. Dr. Caffé  completed his internship and residency (Internat des Hôpitaux and began his career in medicine at the academic hospitals of Assistance Publique de Paris.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.